Article Text

Download PDFPDF

  1. L. Kearsley-Fleet1,
  2. E. Baildam2,
  3. M. Beresford2,3,
  4. H. Foster4,5,
  5. T. Southwood6,
  6. W. Thomson7,8,
  7. K. Hyrich1,8
  8. on behalf of BCRD and BSPAR-ETN study groups
  1. 1The University of Manchester, Manchester Academic Health Science Centre, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom
  2. 2Alder Hey Children’s NHS Foundation Trust, Clinical Academic Department of Paediatric Rheumatology, Liverpool, United Kingdom
  3. 3University of Liverpool, Institute of Life Course and Medical Sciences, Liverpool, United Kingdom
  4. 4Newcastle University, Population Health Institute, Newcastle Upon Tyne, United Kingdom
  5. 5Great North Children’s Hospital, Paediatric Rheumatology, Newcastle Upon Tyne, United Kingdom
  6. 6University of Birmingham and Birmingham Children’s Hospital, Institute of Child Health, Birmingham, United Kingdom
  7. 7The University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester, United Kingdom
  8. 8Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester, United Kingdom


Background: Biologic therapies have revolutionised treatment pathways and outcomes for patients with juvenile idiopathic arthritis (JIA). Although there is a choice of approved TNF inhibitors available as a first biologic, there lacks data to inform treatment choices in clinical practice.

Objectives: To compare short-term outcomes on etanercept and adalimumab in children and young people with JIA without uveitis, including drug survival, arthritis disease activity and function ability at 1 year.

Methods: All patients starting a first biologic (etanercept/adalimumab including biosimilars) from 2010 in the UK JIA biologic registers (BCRD and BSPAR ETN) were included. Those with systemic JIA or with any history of uveitis were excluded. Data were collected at start of therapy, 6 months, 1 year, and then annually, including patient demographic, disease activity and drug therapy. In this analysis, drug survival and arthritis disease activity / function ability at 1 year (range 3-15 months) were investigated; comparing between therapies using logistic / linear regression, adjusted for propensity deciles.

Results: There were 550 patients with outcome data available (to 30 Sept 2020); 384 etanercept, 166 adalimumab. At registration, 68% female, median age 12 years old (IQR 8-14), median disease duration 1 year (IQR 1-4), 72% on concomitant methotrexate. Disease activity was similar between both therapies at baseline and one year. At one year, 70% were still on biologic therapy; most stopping therapy for ineffectiveness (45%), adverse events (31%), or patient / family choice (15%). Inactive disease and minimal disease activity was achieved in 26% and 46% respectively, 48% achieved a minimally clinical important improvement in their functional ability (CHAQ improvement >0.13).

Conclusion: This is the first comparative effectiveness analysis of adalimumab and etanercept within UK children receiving TNFi therapies for JIA. Despite large patient numbers, there was no evidence of difference between adalimumab and etanercept regarding arthritis disease control or treatment persistence. For children without uveitis, both adalimumab and etanercept can be considered as effective treatment options for children and young people with JIA.

Disclosure of Interests: None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.